Y-mAbs Therapeutics New Drug Application Gets FDA Clearance
By Denny Jacob
Y-mAbs Therapeutics' investigational new drug application for CD38-SADA was cleared by the Food and Drug Administration.
The commercial-stage biopharmaceutical company said CD38-SADA is its second program within its self-assembly disassembly pre-target radioimmunotherapy theranostic platform. The Phase 1 trial is investigating the safety and tolerability of the CD38-SADA: (177) Lu-DOTA Drug Complex in patients with relapsed or refractory non-Hodgkin lymphoma.
Interim Chief Executive Thomas Gad said the FDA's clearance marks the second program utilizing its SADA technology platform to enter clinic development within just 15 months.
Y-mAbs said it expects to dose the first patient in its Phase 1 trial in 2024.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
October 17, 2023 17:46 ET (21:46 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
What’s Happening in the Markets This Week
-
Worst-Performing Stock ETFs of the Quarter
-
Q3 in Review and Q4 2024 Market Outlook
-
Top-Performing Stock ETFs of the Quarter
-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Consumer Defensives: Despite Angst, Thirsty Investors Have Names to Pursue
-
Industrials: Many Stocks Overvalued After Q3 Outperformance
-
Basic Materials: Despite Index Rise, We See Multiple Long-Term Opportunities
-
What the Election Could Mean for Big Tech Stocks
-
3 Lessons From Recent Stock Market Drama
-
Consumer Cyclicals: Even Amid Moderating Consumer Spending, We See Discounts
-
Healthcare: Valuations Look Fair Overall, With Select Industries Still Undervalued
-
Utilities: Falling Interest Rates, Growth Outlook Boosting Stocks